Back to Search Start Over

Is the Combination of Platelet-Rich Plasma and Hyaluronic Acid the Best Injective Treatment for Grade II-III Knee Osteoarthritis? A Prospective Study.

Authors :
Ciapini G
Simonettii M
Giuntoli M
Varchetta G
De Franco S
Ipponi E
Scaglione M
Parchi PD
Source :
Advances in orthopedics [Adv Orthop] 2023 Mar 10; Vol. 2023, pp. 1868943. Date of Electronic Publication: 2023 Mar 10 (Print Publication: 2023).
Publication Year :
2023

Abstract

Background: Knee osteoarthritis is a common disease with increasing incidence and prevalence in western countries. It can cause severe pain and functional limitations, thereby representing a threat for patients' quality of life and a burden for national health systems. Intra-articular injections with hyaluronic acid (HA) and platelet-rich plasma (PRP) have been used for decades in order to reduce the symptoms caused by osteoarthritis. In recent years, a combination of HA and PRP has been introduced in clinical practice with the aim to minimize the clinical presentation of osteoarthritis and potentially delay articular degeneration.<br />Materials and Methods: Sixty cases with grade II-III knee osteoarthritis according to the Kellgren-Lawrence classification were included in a prospective study, focused on the evaluation of clinical and functional outcomes after intra-articular knee injections. Cases were randomly divided into three groups. Twenty cases (Group A ) were injected with HA, 20 (Group B ) had PRP, and the remaining 20 (Group C ) received a combination of HA and PRP. Basal WOMAC score and VAS score were recorded before the treatment and repeated within 3 and 6 months after the treatment.<br />Results: At 6-month follow-up, Group C (PRP + HA) was the one with the lowest WOMAC and VAS mean values. It was also the only group that reported a reduction in the two values both in the first three months and in the following three months. No major complication was recorded.<br />Conclusion: The combination of platelet-rich plasma and hyaluronic acid can be effective in the treatment of grade II-III knee osteoarthritis in a short-to-mid-term scenario. It represents an innovative and valuable alternative to the administration of its two components alone.<br />Competing Interests: The authors declare that they have no conflicts of interest.<br /> (Copyright © 2023 Gianluca Ciapini et al.)

Details

Language :
English
ISSN :
2090-3464
Volume :
2023
Database :
MEDLINE
Journal :
Advances in orthopedics
Publication Type :
Academic Journal
Accession number :
36938102
Full Text :
https://doi.org/10.1155/2023/1868943